PDF
(Download)
|
- Tongkat Ali (Eurycoma longifolia, Simaroubaceae)
- Erectile Dysfunction
- Toxicology
- Review
|
Date:
11-30-2016 | HC# 051652-557
|
Re: Beneficial Bioactivities of Tongkat Ali Are Diverse and May Include Treatment of Erectile Dysfunction
Rehman
SU, Choe K, Yoo HH. Review on a traditional herbal medicine, Eurycoma longifolia Jack (Tongkat Ali):
Its traditional uses, chemistry, evidence-based pharmacology and toxicology. Molecules. March 2016;21(3):331. doi:
10.3390/molecules21030331.
Eurycoma longifolia (Simaroubaceae), known
traditionally as Tongkat Ali, is a shrubby tree native to Southeast Asia,
Malaysia, and Indonesia. Traditionally, water decoction of the root is consumed
as a tonic or adaptogen, as a panacea for a wide variety of discomforts, and to
treat conditions including malaria, sexual dysfunction, cancer, and diabetes. Currently,
the raw crude root powder is consumed. There are several categories of bioactive
components, but quassinoids are the most numerous. The quantity of quassinoids
measured via liquid chromatography-mass spectrometry (LC-MS) can be used to
confirm purity of Tongkat Ali and for product identification. This review
article describes the uses of Tongkat Ali and the scientific evidence
supporting its use. This review includes many references, and each scientific
study is described very briefly. As a consequence, this HerbClip summarizes the
data with equal brevity.
Tongkat
Ali is used to enhance male fertility. Studies in rats demonstrate that Tongkat
Ali increases semen volume, spermatogenesis, spermatozoa count and motility,
testosterone steroidogenesis in Leydig cells, plasma testosterone levels,
penile reflexes, and sexual behavior including mounting and ejaculation, and
decreases hesitation time.
The
authors describe six clinical trials and one meta-analysis that evaluated Tongkat
Ali for related uses in men. Three randomized, placebo-controlled, human trials
(RCTs) evaluated a proprietary freeze-dried water extract (Physta®;
Biotropics Malaysia Berhad; Selangor, Malaysia). In one study, men (n = 109; aged
30-55 years) were treated with 300 mg Physta or placebo for 12 weeks. The Physta
group had improvements in overall erectile function scores (P < 0.001), a 14%
increase in libido, a 44.4% increase in sperm motility, and an 18.2% increase
in semen volume. It is unclear whether these increases are compared with
baseline or placebo. In the second RCT, male recreational athletes (number and
age not reported [NR]) were treated with 400 mg/day Physta or placebo for six weeks.
There were no significant differences between groups in the ratio of testosterone:epitestosterone,
liver function, or renal function. In the third RCT, healthy men (n = NR; aged
40-65 years) were treated with Physta (dose NR) or placebo for 12 weeks. Sexual
intercourse attempts, erection quality, and measures of sexual health and
"aging male symptom[s]" improved more in the Physta group (P <
0.05 for all). Physta was well tolerated. A meta-analysis of RCTs of Tongkat
Ali compared to placebo concluded that current evidence supports a clinical
effect on erectile dysfunction, but a recommendation for its use could not be
made without additional research.
An
open-label study of men (n = 350; age NR) treated with 200 mg/day Tongkat Ali (duration
NR) analyzed semen every three months up to nine months. Unspecified semen
parameters improved, and there were 11 spontaneous pregnancies [stated without
explanation to be "14.7%"]. In a second study, men with late-onset
hypogonadism were treated with Tongkat Ali
(dose and duration NR). Patients had a significant improvement in the
Ageing Males' Symptoms score and serum testosterone concentration compared with
baseline (P < 0.0001). In a pilot study, physically active men and women (n
= NR; aged 57-72 years) were treated with 400 mg/day Tongkat Ali for five weeks
to evaluate its ergogenic effect (enhancing physical performance) in elderly
people. Muscle strength improved and total and free testosterone concentrations
increased in men and women compared with baseline (P values not given).
Tongkat
Ali has dose-dependent activity in vitro against Plasmodium falciparum, which causes malaria. The quassinoids may
contribute to the activity; synergy among multiple active compounds is apparent.
No human or animal studies were reported.
In
vitro, Tongkat Ali root extracts or fractions are cytotoxic and
antiproliferative in human cancer cell lines, including lung, breast, colon,
and cervical cancers, melanoma, fibrosarcoma, and epidermoid carcinoma of the
nasopharynx. In particular, the compounds 9-methoxycanthin-6-one and
canthin-6-one were most cytotoxic against human lung and breast cancer cell
lines, and one fraction caused apoptosis (cell death) in breast cancer cells. The
compound eurycomanone caused apoptosis in an ovarian cancer cell line. Eurycomanone
and eurycomanol can regulate signaling pathways involved in proliferation, cell
death, and inflammation. Fractions of the root extract show activity against
acute promyelocytic leukemia and chronic myelogenous leukemia, the latter also
in vivo. Tongkat Ali did not have significant cytotoxic effects on
normal/healthy cell lines. In vivo, it is reported to inhibit subcutaneous
tumor growth and angiogenesis.
Alcoholic
and acetone extracts of the leaves and stems, but not the roots, have activity
against the Gram-negative bacteria Escherichia
coli and Salmonella typhi. Aqueous
leaf extract had activity against
Staphylococcus aureus and Serratia marcescens.
The beta-carboline
alkaloids of Tongkat Ali produced anti-inflammatory activity in vitro. A
hydroalcoholic extract had antioxidant activity (free radical scavenging) in
vitro, and dose-dependent inflammatory activity.
The
antianxiety effects of fractions of Tongkat Ali were compared with the positive
control diazepam in vivo. The fractions had similar antianxiety effects as
diazepam in multiple tests in rats. In an RCT, subjects (n = 63; age NR) with
moderate stress were treated with a hot-water extract of Tongkat Ali (dose NR)
or placebo daily for four weeks. Eurycoma
longifolia improved stress hormone levels and "certain mood state
parameters" (no additional details were provided).
In
diabetic rats, but not normoglycemic rats, two aqueous extracts of Tongkat Ali
decreased blood glucose levels by 38% and 47% (P < 0.05 and P < 0.001,
respectively). In vitro, root extract increased insulin sensitivity and glucose
uptake and suppressed lipid accumulation dose-dependently.
In
vivo, Tongkat Ali prevented bone calcium loss in orchidectomised rats. Thus, it
has a potential use for androgen-deficient osteoporosis in men. Its testosterone-enhancing
effects can stimulate osteoblast proliferation and differentiation, increasing
the bone formation rate. Androgen-deficient osteoporosis is treated with
testosterone, which can have unwanted side effects. The authors suggest that
future studies can evaluate Tongkat Ali plus a lower dose of testosterone to
see if the combination can reduce side effects while maintaining efficacy.
Several
miscellaneous effects have been reported. An extract of Tongkat Ali normalized
irregular estrous cycles and reduced testosterone-induced ovarian follicular
damage in rats. Tongkat Ali in smoke from mosquito coils increased mosquito
knockout but not death. In vivo, Tongkat Ali increased the weight of the levator
ani muscle (involved in tail wagging) in castrated animals. In vitro and in
vivo studies have reported that it can inhibit gastric ulcers.
A
few of the active compounds, including eurycomanone and 9-methoxycanthin-6-one,
are reported to have poor oral bioavailability. Eurycomanone does not inhibit
liver cytochrome P450 (CYP) enzymes, which are involved in drug/herb
metabolism. However, Tongkat Ali has a weak, concentration-dependent inhibitory
effect on CYP1A2, CYP2A6, and CYP2C19 isozymes in vitro. The authors state that
caution should be advised when taking extracts with conventional drugs. [Note: However,
false positives with such in vitro assays are common.]
Despite
historical use, the safety of Tongkat Ali has been formally assessed only since
the late 1990s. The
composition of ethanolic, n-butanolic-, and aqueous-based fractions differs;
consequently, the safety of each differs as well. The water-based fraction is
considered the safest, with a Lethal Dose 50 (LD50) in rats of
>3000 mg/kg body weight; another study reports an LD50 of >6
g/kg. In rat models, the aqueous extract Physta did not produce histopathological
changes or acute toxicity after 90 days of treatment at doses of 250-2000
mg/kg/day. A quassinoid-rich extract was used in a two-generation reproductive
toxicity study; no negative effects on fetuses were seen, and treated rats had
larger litters than controls.
One
study calculated the acceptable daily intake for adult humans to be up to 1.2
g/day, based on the levels seen to be harmless in rats; however, the type of
extract used in that study was not specified. In humans, 400 mg/day Physta for
six weeks did not produce any toxicity to liver or kidney function. Tongkat Ali is
considered safe in the usually recommended doses of 200-400 mg daily. The
Endocrine Society recommends that men with prostate cancer avoid testosterone
treatment. Since Tongkat Ali increases testosterone levels, it may have hypothetical risks for elderly
men, who frequently have undetected indolent prostate cancers. It should also
be used with caution in patients taking hypoglycemic agents and in patients
with weak immune systems. This review suggests that it should be avoided by
pregnant or lactating women (due to lack of research in humans). It quotes
secondary sources as claiming that use should be avoided by people who have
"breast cancer, prostate cancer, heart disease, kidney disease, liver
disease, or sleep apnea … .," though there seems to be no specific
rationale for most of these warnings.
The
authors acknowledge that more research is needed to evaluate efficacy. The
research to date can be viewed as a basis to help guide future in vivo and
clinical studies. The authors also suggest that Tongkat Ali could be a valuable
source of lead compounds for drug development.
—Heather S. Oliff,
PhD
|